Alkermes Raises Avadel Acquisition Offer to $2.37B, Outmaneuvering Lundbeck With Superior CVR Terms
Alkermes has increased its offer to acquire Avadel to $22.50 per share, valuing the deal at up to $2.37 billion.
News
Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
IQWiG: No Added Benefit for Darolutamide Over Apalutamide Without Direct Comparative Data
IQWiG has concluded that darolutamide offers no proven added benefit over apalutamide for metastatic hormone-sensitive prostate cancer.
CMS Sets 2026 Medicare Premiums and Deductibles as Costs Rise and Policy Changes Take Effect
CMS Sets 2026 Medicare Premiums and Deductibles as Cost Pressures Mount and Regulatory Fixes Temper Increases The Centers for Medicare & Medicaid Services (CMS) has released the 2026 Medicare Parts A and B premiums, deductibles, and income-related adjustment amounts, outlining another year of steady cost increases across the program. While the updates reflect predictable inflationary … Read more
NICE Expands Cancer and Dermatology Options With Three Major Recommendations Across DLBCL, Myeloma, and Chronic Hand Eczema
NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.
Vietnam Targets 2026 Rollout of Free Annual Health Checks and Expanded Insurance Coverage
Doctors providing check-ups with a sign announcing free annual health checks and expanded insurance. Vietnam Sets Ambitious 2026 Plan for Free Annual Health Checks, Expanded Coverage, and System-Wide Reform Vietnam is preparing to deliver one of its most far-reaching public-health reforms in decades, a nationwide guarantee of one free annual health check or screening for … Read more
Biogen’s High-Dose Nusinersen Wins CHMP Backing for Enhanced SMA Treatment
Biogen has earned a positive CHMP opinion for its high-dose nusinersen regimen, supported by strong DEVOTE study results showing major motor improvements and reduced mortality risk in SMA patients.
Novo Nordisk Cuts Wegovy and Ozempic Self-Pay Price to $199 in New Access Push
Novo Nordisk has introduced a $199 introductory price for Wegovy and Ozempic starter doses, alongside a permanent drop in monthly self-pay costs to $349.
J&J’s $3B Halda Deal Sets Up $50B Oncology Push
J&J is acquiring Halda Therapeutics for $3.05B, gaining a precision prostate cancer therapy and a breakthrough induced-proximity platform.
EMA, CHMP NOVEMBER 2025 MEETING: TEN NEW APPROVALS, FOUR INDICATION EXTENSIONS
CHMP’s November 2025 meeting delivered 10 new drug approvals, four indication extensions, and several high-profile withdrawals, highlighting continued momentum in gene therapy, oncology, immunology, and diagnostics.